SUTRO BIOPHARMA, INC. — Director's Dealing 2021

Jan 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2021-01-26

Reporting Person: Hallam Trevor (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-26	Common Stock	M	2393	$4.36	Acquired	58510	Direct
2021-01-26	Common Stock	S	2228	$25.683	Disposed	56282	Direct
2021-01-26	Common Stock	S	165	$26.0979	Disposed	56117	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-26	Employee Stock Option (right to buy)	$4.36	M	2393	Disposed	2021-02-08	Common Stock (2393)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.05 to $25.91 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.05 to $26.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The option is fully vested and exercisable.